Investors in the clinical-stage biotechnology company Kezar Life Sciences (NASDAQ: KZR) saw a 46% rise in stock this morning after the company announced interim results regarding a Phase 2 trial of KZR-616 – a new treatment for patients with proliferative lupus nephritis (LN).
Part of the companies MISSION clinical trials in order to test the responder rate of KZR-616 – The 24 week period proved critical in evaluating the success of the new treatment; in which patients received 60mg of KZR-616 once weekly in addition to existing background treatment.
The study was constructed with two points of efficacy, the first being the proportion of patients achieving a renal response measured by a 50% or greater reduction in urine protein to creatinine ratio at the end of the treatment. The second was the number of patients with a total renal response or partial renal response. The results showed 3 out of 5 patients were recorded with a 50% or more reduction in UPCR at week 25, with 4 out of 5 patients demonstrating a reasonable reduction in proteinuria to less than 0.8UPCR.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
KZR stock was trading sideways until a spike in August reassured investors that the company still had a lot of growth potential. Following positive Q3 results just last week, it didn’t take much for investors to jump back on board – leaving the market heavily occupied by bulls thirsty for a slice of cutting-edge success.
Should You Invest in Kezar Life Sciences Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
